Fig 1: Doxorubicin impeded CLEC-2-induced platelet aggregation via anti-CLEC-2 agonist binding. Representative aggregation curve demonstrating no aggregation induced by Dox; ADP agonist control to stimulate normal platelet aggregation, assessed by light-transmission aggregometry (A). Human platelet-rich plasma (PRP) aggregation induced by the CLEC-2 agonist, Fucoidan, following ∼5 min Dox or vehicle control treatment (B). Representative aggregation curve and bar graph of human PRP aggregation induced by anti-CLEC-2 mAb agonist (C), or classical agonists ADP (D), Collagen/CRP (E and F), and TRAP6 (G) following Dox or vehicle control pretreatment. Representative aggregation curve and bar graph of mouse PRP aggregation induced by antimouse CLEC-2 mAb (H) or the traditional agonist, CRP (I). n = 3 to 5 for all assays. Values in bar graphs are displayed as mean ± SD. For comparison of multiple groups, a repeated measures one-way analysis of variance with multiple comparison tests was used on data normalized to respective controls within each experiment, where p < 0.05 (∗), p < 0.01 (∗∗), p < 0.0001 (∗∗∗∗), ns = not significant. CLEC-2, C-type lectin-like receptor 2; CRP, collagen-related peptide; Dox, doxorubicin; GPIbα, glycoprotein 1bα; IgG, immunoglobulin G; mAb, monoclonal antibody; PRP, platelet-rich plasma; TRAP6, thrombin receptor-activating peptide 6.
Fig 2: Doxorubicin and CLEC-2 antibody-induced GPIbα shedding via SYK transduction was mediated by ADAM17 metalloproteinase, independent of integrin αIIbβ3. Surface GPIbα expression on human platelets pre-treated with 300 μM Piceatannol measured by flow cytometry following 4 h Dox treatment (A) or anti-CLEC-2 mAb (B). Human platelets pre-treated with 100 μM GM6001 measured for GPIbα expression by flow cytometry following 4 h treatment with Dox (C) or anti-CLEC-2 mAb (D). Flow cytometric analysis for inhibition of Dox-induced GPIbα shedding on mouse platelets treated with ADAM10 specific inhibitor GI254023X (E) or ADAM10/17 selective inhibitor GW280264X (F). Analysis of inhibition for anti-CLEC-2 mAb-induced GPIbα shedding from mouse platelets by GI254023X (G) or GW280264X (H). Quantification of GPIbα surface expression following anti-CLEC-2 mAb-induced shedding on platelets from integrin αIIbβ3 genetic knockout mouse platelets (I). Data represented by bar graph as mean ± SD, n = 4 to 6 for all assays. For comparison of multiple groups, a repeated measures one-way analysis of variance with multiple comparison tests was used on data normalized to respective controls within each experiment, where p < 0.05 (∗), p < 0.01 (∗∗), p < 0.001 (∗∗∗), p < 0.0001 (∗∗∗∗), ns = not significant. CLEC-2 mAb, C-type lectin-like receptor 2 monoclonal antibody; Ctr, control; Dox, doxorubicin; GI, GI254023X; GPIbα, glycoprotein Ibα; GW, GW280264X; Pice, piceatannol.
Fig 3: Anti-CLEC-2 antibody-induced GPIbα shedding from platelets. Surface GPIbα expression on platelets measured by flow cytometry following 4 h anti-CLEC-2 mAb treatment of human (A) and mouse (B) platelets. Data are represented by histogram (left) and bar graph (right). n = 4. Total supernatant and cell lysate fractions from human platelets treated with anti-CLEC-2 mAb were assessed by Western blot analysis using anti-glycocalicin antibody to probe the N terminus of GPIbα (C). Western blot densitometry quantification from lysates and supernatants (D). n = 3. Positions of molecular mass markers indicated on the left and right of the representative blots. Values in bar graphs are displayed as mean ± SD. For comparisons of multiple groups, a repeated measures one-way analysis of variance with multiple comparison tests was used on data normalized to respective controls within each experiment, where p < 0.05 (∗), p < 0.01 (∗∗), p < 0.0001 (∗∗∗∗), ns = not significant. 2o, secondary; CLEC-2, C-type lectin-like receptor 2; Ctr, control; Dox, doxorubicin; GPIbα, glycoprotein Ibα; hPlts, human platelets; IgG, immunoglobulin G; Iso, isotype; mAb, monoclonal antibody; mPlts, mouse platelets; SN, supernatant.
Fig 4: Doxorubicin directly bound recombinant CLEC-2 protein. ITC thermogram showing interaction between CLEC-2 and Dox (A); no interaction between Fc tag and Dox (B); heat of dilution of Dox (C). For each, on top is the raw titration data showing the heat resulting from each injection of ligand into buffer solution. The bottom shows the integrated heat plot after correcting for the heat of dilution. All experiments were performed at 25 °C in TB (pH 7.4). Binding affinity is reported as mean ± SD from two independent experiments. In silico docking prediction of the interaction between Dox and the extracellular region of CLEC-2 in cartoon structure (D). Surface view highlighting the docking of Dox and CLEC-2 with key interfacing Arg residues (E). Detailed representation of specific intermolecular bonds between Dox and surrounding CLEC-2 Arg residues, with hydrogen bonds depicted as dashed lines (F). Arg, arginine; CLEC-2, C-type lectin-like receptor 2; Dox, doxorubicin; H.o.D, heat of dilution; ITC, isothermal titration calorimetry; TB, Tyrode’s buffer.
Fig 5: Anti-CLEC-2 Antibody Induced GPIbα Shedding in vivo. Time series analysis and representative direct comparison at 1 h for surface expression of GPIbα (A and B), integrin β3 (C and D), and CLEC-2 (E and F) from circulating platelets as well as platelet counts (G and H) in mice following a 0.4 μg/g IV dosage of anti-CLEC-2 mAb or isotype control IgG. Antibody or IgG control was injected and samples of circulating platelets were collected via saphenous bleeding at the respective time points then analyzed for the indicated receptor by flow cytometry. n = 4 to 6. Values are plotted as mean ± SD. A two-way ANOVA was performed to determine difference between treatment groups indicated by the black bracket and asterisks, while a repeated measures one-way ANOVA with multiple comparisons determined deviation from baseline and is indicated by the blue asterisks (A, C, E, and G), in both cases on data normalized to respective controls within each experiment. To compare difference in receptor expression at 1 h postinjection between isotype- and Ab-receiving groups, a two-tailed unpaired student’s t test was performed (B, D, F, and H). CLEC-2, C-type lectin-like receptor 2; GPIbα, glycoprotein Ibα; IgG, immunoglobulin G; Iso Ctr, isotype control; mAb, monoclonal antibody; Plt, platelet.
Supplier Page from BioLegend for Recombinant Mouse CLEC2-Fc Chimera (carrier-free)